Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: A clinical consideration

Inflammation Research

Volumn 47, Issue SUPPL. 2, 1998, Pages

  Kawai, S ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

COX selectivity; Gastrointestinal complications; Nonsteroidal anti inflammatory drugs (NSAIDs); Rheumatoid arthritis

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETODOLAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; LOXOPROFEN; MECLOFENAMIC ACID; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; SALSALATE; SULINDAC; TOLMETIN; ZALTOPROFEN;

BONE MARROW DEPRESSION; CONFERENCE PAPER; DRUG SAFETY; DRUG SELECTIVITY; ENZYME ASSAY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FAILURE; PEPTIC ULCER; RISK ASSESSMENT;

EID: 0031752836     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050291     Document Type: Conference Paper

References (18)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
2. Flower RJ, Gryglewski R, Herbaczynska-Cedro K, Vane JR. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nature 1972;238:104-6.
3. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6.
4. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266: 12866-72.
5. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol 1996;25:9-21.
6. Emery P. Clinical implications of selective cyclooxygenase-2 inhibition. Scand J Rheumatol 1996;25:23-8.
7. Crofford LJ, Wilder RL, Ristimäki AP, Sano H, Remmers EF, Epps HR, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095-101.
8. Sano H, Hla T, Maier JAM, Crofford LJ, Case JP, Maciag T, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992;89:97-108.
9. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
10. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, et al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998;347:87-94.
11. Myllykangas-Luosujärvi R, Aho K, Isomäki H. Death attributed to anti-rheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol 1995;22:2214-7.
12. 2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 1997;329:181-7.
13. Yanagawa A, Kanemitsu K, Kawai S, Hoshi K, Shimada J, Mizushima Y. Phase I clinical trial of aceclofenac - a placebo controlled double blind study. XVIIIth ILAR Congress of Rheumatology, 1993:491.
14. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-34.
15. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47:55-9.
16. Appleton I, Tomlinson A, Willoughby DA. Inducible cyclooxygenase (COX-2): A safer therapeutic target? Br J Rheumatol 1994;33:410-2.
17. Henry D, Lim LL-Y, Rodriguez LAG, Gutthann SP, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. Br Med J 1996;312: 1563-6.
18. Singh G, Terry R, Ramey D, Halpern J, Brown WB. Comparative GI toxicity of NSAIDs. XIXth ILAR Congress of Rheumatology, 1997:159.